HOME >> MEDICINE >> NEWS
At Johns Hopkins: Emphasis on improved care and faster access to services shortens hospital stays

provide more of it without long wait times and to the better satisfaction of the patients we serve," says JHH physician in chief Myron Weisfeldt, M.D., who also is a professor and director of the Department of Medicine at The Johns Hopkins University School of Medicine. "Our next step is to strengthen this program as part of the management culture within Hopkins and to see if other hospitals can adopt our efforts to form the basis of a national program."

Weisfeldt noted that "spending four or five days in the hospital is not uncommon for many patients and for a variety of illnesses and conditions, but we need to question whether or not it is really necessary to spend so much time in an acute-care setting."

Indeed, he added, "most patients would rather not be in a hospital, preferring to return home as quickly as possible and, provided that it is safe to do so, to finish recuperating in the comfort of their own surroundings." The goal, Weisfeldt says, is to provide the best care, and "sometimes that means longer stays, sometimes not."

Historically, the dilemma for physicians and patients, he says, has always been to determine when it is best to leave the hospital, confident that the patient is on a road to recovery and that the patient's care has been delivered in the most effective and efficient manner possible.

Fiscal pressures compound the dilemma, with government, private payers and regulators eager to justify time spent and keep expensive hospital stays to a minimum. An average day of hospital care can cost $1,500.

"It is a tough judgment call that requires more than medical training; it requires constant questioning and review of how we manage a large hospital, practice medicine and treat our patients," says kidney specialist Paul Scheel Jr., M.D., an associate professor and vice chairman of medicine at Hopkins.

To put some evidence behind long-held suspicions that patients could be served better with a
'"/>

Contact: David March
dmarch1@jhmi.edu
410-955-1534
Johns Hopkins Medical Institutions
19-Sep-2005


Page: 1 2 3 4 5 6 7

Related medicine news :

1. Johns Hopkins begins aggressive screening for superbugs in children
2. Johns Hopkins develops pancreas cancer risk model
3. March of Dimes, Johnson & Johnson Pediatric Institute launch prematurity prevention partnership
4. Diagnosis and referrals for kidney disease fall well short of need, Johns Hopkins study shows
5. Johns Hopkins Childrens Center to lead largest-ever study on kidney disease in children
6. Johns Hopkins lab scientists tame overactive CF protein
7. Two tests better than one for diabetes control, Johns Hopkins expert tells doctors
8. Johns Hopkins scientists exploit novel route to reverse enlarged hearts in obese mice
9. Johns Hopkins scientists map brain area that may aid hunt for human brain stem cells
10. Johns Hopkins study suggests link between caffeine dependence and family history of alcoholism
11. Johns Hopkins flu expert calls for mandatory vaccination of health care workers

Post Your Comments:
(Date:7/30/2015)... ... 30, 2015 , ... Zaca Life has created Recovery Chewable ... water needed, the refreshing berry-flavored tablets are the perfect travel companion. , “We ... that may help with body detoxification, protection and hydration,” said Mark Aleks, Zaca ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American Telemedicine Association (ATA) ... Tradeshow focused exclusively on telemedicine, telehealth and mHealth. The meeting, expected to attract ... take place May 14-17, 2016 in Minneapolis, MN. , ATA’s annual meeting attracts ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Orange, Riverside, Los Angeles, and San Bernardino counties, today announced that Dr. Michael ... Care Administrator. Dr. Demoratz is a strong proponent of early access to palliative ...
(Date:7/30/2015)... ... 2015 , ... The Beryl Institute announces its sixth annual ... Patient Experience Institute, these offerings reinforce the commitment to help frame and expand ... the experience movement, and provide information and research to support expanded focus and ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Mesothelioma Applied Research ... Patient Registry Act of 2015’. The bill was introduced in Congress yesterday by ... Betty McCollum (D-MN), Joe Kennedy (D-MA), and Leonard Lance (R-NJ). The purpose of ...
Breaking Medicine News(10 mins):Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2
(Date:7/29/2015)... July 30, 2015 Roche (SIX: RO, ROG; ... cobas® EGFR Mutation Test v2 for Premarket Approval ... (FDA), as a companion diagnostic test for AZD9291, ... cancer patients with an acquired resistant mutation.  ... who have adenocarcinoma with tumor containing an EGFR ...
(Date:7/29/2015)... 2015  Unilife Corporation ("Unilife" or the "Company") (NASDAQ: ... and supplier of injectable drug delivery systems, today announced ... the Company with flexibility and control to support its ... an equity purchase agreement for up to $45 million ... Chicago -based institutional investor, which provides the ...
(Date:7/29/2015)... BERKELEY, Calif. , July 29, 2015 /PRNewswire/ ... of the Daiichi Sankyo Group, announced today that ... clinical trial results demonstrating that the investigational drug, PLX3397, ... in most patients with tenosynovial giant cell tumor (TGCT), ... tendon sheath. Following phase 1 dose-escalation, which ...
Breaking Medicine Technology:Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 2Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 3Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4Unilife Announces Multifaceted Financing Strategy 5Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 2Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 3Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 4Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 5
Cached News: